Market Cap
US$6.5b
Last Updated
2021/09/18 22:02 UTC
Data Sources
Company Financials +
Executive Summary
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. More Details
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with reasonable growth potential.
Similar Companies
Share Price & News
How has Exelixis's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EXEL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: EXEL's weekly volatility (8%) has been stable over the past year.
Market Performance
7 Day Return
3.8%
EXEL
0.5%
US Biotechs
-0.6%
US Market
1 Year Return
-22.7%
EXEL
25.9%
US Biotechs
33.8%
US Market
Return vs Industry: EXEL underperformed the US Biotechs industry which returned 25.7% over the past year.
Return vs Market: EXEL underperformed the US Market which returned 33.8% over the past year.
Shareholder returns
| EXEL | Industry | Market | |
|---|---|---|---|
| 7 Day | 3.8% | 0.5% | -0.6% |
| 30 Day | 16.5% | 5.5% | 2.0% |
| 90 Day | -7.5% | 7.8% | 4.7% |
| 1 Year | -22.7%-22.7% | 27.5%25.9% | 35.8%33.8% |
| 3 Year | 23.6%23.6% | 20.4%14.9% | 60.0%50.1% |
| 5 Year | 39.2%39.2% | 48.9%37.2% | 123.0%98.7% |
Long-Term Price Volatility Vs. Market
How volatile is Exelixis's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
What Kind Of Investors Own Most Of Exelixis, Inc. (NASDAQ:EXEL)?1 month ago | Simply Wall St
This Just In: Analysts Are Boosting Their Exelixis, Inc. (NASDAQ:EXEL) Outlook for This YearValuation
Is Exelixis undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: EXEL ($20.72) is trading below our estimate of fair value ($75.54)
Significantly Below Fair Value: EXEL is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: EXEL is poor value based on its PE Ratio (69.4x) compared to the US Biotechs industry average (25x).
PE vs Market: EXEL is poor value based on its PE Ratio (69.4x) compared to the US market (17.8x).
Price to Earnings Growth Ratio
PEG Ratio: EXEL is poor value based on its PEG Ratio (1.9x)
Price to Book Ratio
PB vs Industry: EXEL's PB Ratio (3.2x) is in line with the US Biotechs industry average.
Future Growth
How is Exelixis forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
36.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EXEL's forecast earnings growth (36.2% per year) is above the savings rate (2%).
Earnings vs Market: EXEL's earnings (36.2% per year) are forecast to grow faster than the US market (14.9% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: EXEL's revenue (17.7% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: EXEL's revenue (17.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EXEL's Return on Equity is forecast to be low in 3 years time (17.9%).
Past Performance
How has Exelixis performed over the past 5 years?
23.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EXEL has high quality earnings.
Growing Profit Margin: EXEL's current net profit margins (8.1%) are lower than last year (28.2%).
Past Earnings Growth Analysis
Earnings Trend: EXEL has become profitable over the past 5 years, growing earnings by 23% per year.
Accelerating Growth: EXEL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: EXEL had negative earnings growth (-66.6%) over the past year, making it difficult to compare to the Biotechs industry average (4.9%).
Return on Equity
High ROE: EXEL's Return on Equity (4.6%) is considered low.
Financial Health
How is Exelixis's financial position?
Financial Position Analysis
Short Term Liabilities: EXEL's short term assets ($1.6B) exceed its short term liabilities ($255.3M).
Long Term Liabilities: EXEL's short term assets ($1.6B) exceed its long term liabilities ($68.9M).
Debt to Equity History and Analysis
Debt Level: EXEL is debt free.
Reducing Debt: EXEL currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Debt Coverage: EXEL has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: EXEL has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Exelixis's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EXEL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EXEL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EXEL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EXEL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EXEL's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
6.2yrs
Average management tenure
CEO
Mike Morrissey (60 yo)
11.17yrs
Tenure
US$2,349,812
Compensation
Dr. Michael M. Morrissey, Ph D., also known as Mike, has been the Chief Executive Officer and President of Exelixis, Inc. since July 2010. Dr. Morrissey served as the President of Research and Development...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD2.35M) is below average for companies of similar size in the US market ($USD6.44M).
Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: EXEL's management team is seasoned and experienced (6.2 years average tenure).
Board Members
Experienced Board: EXEL's board of directors are seasoned and experienced ( 17.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Exelixis, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Exelixis, Inc.
- Ticker: EXEL
- Exchange: NasdaqGS
- Founded: 1994
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$6.528b
- Shares outstanding: 315.05m
- Website: https://www.exelixis.com
Number of Employees
Location
- Exelixis, Inc.
- 1851 Harbor Bay Parkway
- Alameda
- California
- 94502
- United States
Listings
Biography
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company’s products includ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/09/18 22:02 |
| End of Day Share Price | 2021/09/17 00:00 |
| Earnings | 2021/06/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.